Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

371 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Levine RL, Pardanani A, Tefferi A, Gilliland DG. Levine RL, et al. Among authors: pardanani a. Nat Rev Cancer. 2007 Sep;7(9):673-83. doi: 10.1038/nrc2210. Nat Rev Cancer. 2007. PMID: 17721432 Review.
Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
Pardanani A, Tefferi A. Pardanani A, et al. Leuk Res. 2004 May;28 Suppl 1:S47-52. doi: 10.1016/j.leukres.2003.10.006. Leuk Res. 2004. PMID: 15036941 Review.
Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A, Elliott MA, Pardanani A. Tefferi A, et al. Among authors: pardanani a. Mayo Clin Proc. 2006 Apr;81(4):553-63. doi: 10.4065/81.4.553. Mayo Clin Proc. 2006. PMID: 16610578 Review.
Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders.
Pardanani A, Lasho T, McClure R, Lacy M, Tefferi A. Pardanani A, et al. Blood. 2006 Jun 1;107(11):4572-3. doi: 10.1182/blood-2005-12-4988. Blood. 2006. PMID: 16717134 No abstract available.
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. Pardanani AD, et al. Blood. 2006 Nov 15;108(10):3472-6. doi: 10.1182/blood-2006-04-018879. Epub 2006 Jul 25. Blood. 2006. PMID: 16868251
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A. Steensma DP, et al. Among authors: pardanani a. Haematologica. 2006 Dec;91(12 Suppl):ECR57. Haematologica. 2006. PMID: 17194663
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Li CY, Wu W, Ketterling RP, Pardanani A, Tefferi A. Kittur J, et al. Among authors: pardanani a. Cancer. 2007 Jun 1;109(11):2279-84. doi: 10.1002/cncr.22663. Cancer. 2007. PMID: 17440984
Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests.
Tefferi A, Pardanani A. Tefferi A, et al. Among authors: pardanani a. Mayo Clin Proc. 2007 May;82(5):599-604. doi: 10.4065/82.5.599. Mayo Clin Proc. 2007. PMID: 17493421
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. Pardanani A, et al. Leukemia. 2007 Aug;21(8):1658-68. doi: 10.1038/sj.leu.2404750. Epub 2007 May 31. Leukemia. 2007. PMID: 17541402
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Pardanani A, et al. Leukemia. 2007 Sep;21(9):1960-3. doi: 10.1038/sj.leu.2404810. Epub 2007 Jun 28. Leukemia. 2007. PMID: 17597810
371 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback